486422-54-2

Basic information

• Product Name: 4-(4-(tert-butoxycarbonyl)piperazin-1-ylsulfonyl)phenylboronic acid
• Synonyms: 4-(4-(tert-butoxycarbonyl)piperazin-1-ylsulfonyl)phenylboronic acid
• CAS NO: 486422-54-2
• Molecular Formula: C₁₅H₂₃BN₂O₆S
• Molecular Weight: 370.22892
• Product Categories: Boronate Ester;Boronic Acid;Potassium Trifluoroborate
• Mol File: 486422-54-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 547.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• PKA: 8.04±0.16(Predicted)
• CAS DataBase Reference: 4-(4-(tert-butoxycarbonyl)piperazin-1-ylsulfonyl)phenylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(tert-butoxycarbonyl)piperazin-1-ylsulfonyl)phenylboronic acid(486422-54-2)
• EPA Substance Registry System: 4-(4-(tert-butoxycarbonyl)piperazin-1-ylsulfonyl)phenylboronic acid(486422-54-2)

Safety Data

• Hazardous Substances Data: 486422-54-2(Hazardous Substances Data)

Upstream product

• 259808-63-4 4-(4-bromobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester 
• 5419-55-6 Triisopropyl borate 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Relevant articles and documents

Preparation of targeted GSK3 alpha/beta degradation agent and medical application thereof

The invention discloses preparation of a targeted GSK3 alpha/beta degradation agent and a medical application thereof. The pharmaceutical composition comprises compounds or pharmaceutically acceptable salts thereof as shown in general formulas (I) and (II), R is selected from Cl and I, m is selected from 2, 3, 4, 5 and 6, and n is selected from 1, 2 and 4. The invention provides the degradation agent, and the compound disclosed by the invention can effectively degrade cell GSK3 alpha/beta in a targeting manner, and can be used as a therapeutic agent for Alzheimer's disease or other GSK3 protein related diseases.

New phenylpyridylpiperazine compounds

A compound selected from those of formula (I): [image] wherein: X represents a C(O) or SO2 group, R1 represents an aryl group or a group NR3R4 wherein R3 and R4 are as defined in the description, R2 represents an alkyl, (C3-C8)cycloalkyl or (C3-C8)cycloalkyl-(C1-C6)alkyl group, its isomers, and addition salts thereof, and medicinal products containing the same which are useful in treating conditions treatable by antagonists of type H3 central histamine receptors.